Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

US6946441B2 · kind B2 · utility

Assignees

• The Regents of the University of Colorado, a body · US
• The Board of Regents of the University of Texas System · US

Inventors

• Carlin Long · Denver, US
• Eric Olson · Dallas, US
• Michael Bristow · Englewood, US
• Timothy McKinsey · Dallas, US

Key dates

• Filing date: Mar 16, 2004
• Grant date: Sep 20, 2005
• Expiry date: Mar 16, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.